Traumatic Brain Injury Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Traumatic Brain Injury Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034


The 7 major traumatic brain injury markets are expected to exhibit a CAGR of 3.36% during 2024-2034.

The traumatic brain injury market has been comprehensively analyzed in IMARC's new report titled "Traumatic Brain Injury Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Traumatic brain injury refers to damage or disruption to the brain caused by an external force or traumatic event. It occurs when the head experiences a sudden blow, jolt, or penetration, leading to physical, cognitive, and psychological impairments. These injuries can range from mild to severe, and the symptoms can vary widely depending on the location and extent of the damage. Some of the common indications include headaches, dizziness, confusion, difficulty concentrating, mood swings, irritability, depression, sleep disturbances, sensitivity to light or noise, blurred vision, nausea or vomiting, seizures, balance problems, etc. Diagnosing the condition involves a comprehensive evaluation that combines various assessments and medical imaging. Initially, a thorough medical history and physical examination are conducted to determine the presence of indications and identify potential causes. Numerous neuroimaging techniques, such as computed tomography (CT) scans and magnetic resonance imaging (MRI), may be performed to visualize the brain and detect structural abnormalities. Additionally, cognitive tests, neurological assessments, and symptom inventories are utilized to evaluate cognitive functioning, neurological deficits, and psychological changes.

The increasing cases of head injuries caused by falls, motor vehicle accidents, blunt force trauma, assaults, etc., that lead to damage and dysfunction in the brain are primarily driving the traumatic brain injury market. In addition to this, the inflating application of various medications, such as analgesics, anti-seizure drugs, diuretics, stimulants, etc., to manage pain, prevent seizures, reduce brain swelling, and address cognitive symptoms is further bolstering the market growth. Moreover, the escalating utilization of psychological interventions, including cognitive-behavioral therapy and mindfulness-based approaches, that aid in recognizing and modifying negative thoughts, managing emotional difficulties, and developing coping strategies is also creating a positive outlook for the market. Apart from this, the widespread adoption of non-invasive brain stimulation procedures, such as transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS), since they enhance cognition, reduce post-concussion symptoms, and facilitate motor recovery, is acting as another significant growth-inducing factor. Additionally, the ongoing advancements in quantitative imaging techniques, including the introduction of diffusion kurtosis imaging and neurite orientation dispersion and density imaging, which aim to quantify specific aspects of a brain injury like microstructural integrity, white matter connectivity, and network analysis, are expected to drive the traumatic brain injury market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the traumatic brain injury market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for traumatic brain injury and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the traumatic brain injury market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the traumatic brain injury market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the traumatic brain injury market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current traumatic brain injury marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the traumatic brain injury market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the traumatic brain injury market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the traumatic brain injury market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of traumatic brain injury across the seven major markets?
What is the number of prevalent cases (2018-2034) of traumatic brain injury by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of traumatic brain injury by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with traumatic brain injury across the seven major markets?
What is the size of the traumatic brain injury patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of traumatic brain injury?
What will be the growth rate of patients across the seven major markets?

Traumatic Brain Injury: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for traumatic brain injury drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the traumatic brain injury market?
What are the key regulatory events related to the traumatic brain injury market?
What is the structure of clinical trial landscape by status related to the traumatic brain injury market?
What is the structure of clinical trial landscape by phase related to the traumatic brain injury market?
What is the structure of clinical trial landscape by route of administration related to the traumatic brain injury market?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Traumatic Brain Injury - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Traumatic Brain Injury - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Traumatic Brain Injury - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 Traumatic Brain Injury - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Traumatic Brain Injury - Unmet Needs
10 Traumatic Brain Injury - Key Endpoints of Treatment
11 Traumatic Brain Injury - Marketed Products
11.1 List of Traumatic Brain Injury Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 Traumatic Brain Injury - Pipeline Drugs
12.1 List of Traumatic Brain Injury Pipeline Drugs Across the Top 7 Markets
12.1.1 HB adMSC- Hope Biosciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 VAS203 - Vasopharm GmbH
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SB623 cells - SanBio
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. Traumatic Brain Injury - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Traumatic Brain Injury – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Traumatic Brain Injury - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Traumatic Brain Injury - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Traumatic Brain Injury - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Traumatic Brain Injury - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Traumatic Brain Injury - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Traumatic Brain Injury - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Traumatic Brain Injury - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Traumatic Brain Injury - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Traumatic Brain Injury - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Traumatic Brain Injury - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Traumatic Brain Injury - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Traumatic Brain Injury - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Traumatic Brain Injury - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Traumatic Brain Injury - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Traumatic Brain Injury - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Traumatic Brain Injury - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Traumatic Brain Injury - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Traumatic Brain Injury - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Traumatic Brain Injury - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Traumatic Brain Injury - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Traumatic Brain Injury - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Traumatic Brain Injury - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Traumatic Brain Injury - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Traumatic Brain Injury - Access and Reimbursement Overview
16 Traumatic Brain Injury - Recent Events and Inputs From Key Opinion Leaders
17 Traumatic Brain Injury Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Traumatic Brain Injury Market – Strategic Recommendations
19 Appendix

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings